Radioligand Therapy Market To Reach $13,073.9 Million by 2030

The major drivers in the global radioligand therapy market are skyrocketing demand for highly efficient drugs and surging investments in research and development of cancer treatment. In 2021, the market was valued at $7,785.6 million, and it is predicted to touch $13,073.9 million by 2030. Moreover, the market will witness an approximately 6% CAGR from 2021 to 2030. Additionally, this market had witnessed magnificent growth in the count of FDA-approved drugs with the least aftereffects.

To receive free sample pages of this report: https://www.psmarketresearch.com/market-analysis/radioligand-therapy-market/report-sample

The radiopharmaceuticals have the keen interest of numerous researchers for targeted therapy, thereby driving the radioligand therapy market. Therefore, there is an inclination of nuclear medicine physicians toward the development of centralized radio-pharmacies. The major players in the U.S. market are Jubilant Radiopharma and Cardinal Health. Furthermore, all of this is accompanied by extensive government support. The governments not only grant funds but also initiate policies to curb the spread of cancer. In February 2021, Europe's Beating Cancer Plan was initiated by the European Commission, aiming to offer cancer services for early diagnosis.

The fundamental enablers for radiopharmaceuticals are nuclear medicine advancements, which in turn, will play a pivotal role in medicine. There is a rising inclination toward radiopharmaceuticals, to treat and diagnose illnesses including neurological disorders and cancer. Furthermore, FDA had approved numerous radio drugs, including Pluvicto (in 2022), Lutathera (in 2018), and Zytiga (in 2017). These approvals by FDA will not only open the closed opportunities for the highly-competitive market players but also escalate the radiotherapy potential. This is because of their targeted therapeutic irradiation and radioactive decay, being utilized for treating cancer patients.

Inquire before purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=radioligand-therapy-market

Geographically, the U.S. will advance at a swift CAGR in the coming years. The radioligand therapy market is gaining momentum because of the increasing count of research institutions and specialized cancer healthcare centers, coupled with the gradual attempts of the government to enhance chronic illness treatment. Furthermore, the Cancer Moonshot Program is enhanced by the U.S. president in February 2022, to lower the death rate to at least 50% in the next 25 years. Therefore, these increasing government initiatives will augment growth in the market.

Another major driver is the highly-competitive market. The market players are heavily investing in the R&D of radioligand therapy including Johnson & Johnson Services Inc., Pfizer Inc., Radio Medix, ITM Isotope Technologies Munich SE, Molecular Partners, Bayer AG, Telix Pharmaceuticals, POINT Biopharma Global Inc., and Novartis International AG to sustain their position in the market.

About P&S Intelligence

P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies.

Contact:
P&S Intelligence
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.